Liraglutide Injection, Solution
Product Images NDC 50090-8145

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 50090-8145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 01)

Chemical structure diagram of liraglutide showing its amino acid sequence with labeled residues and a C-16 fatty acid (palmitoyl) modification linked to a glutamic acid (Glu) residue. The sequence includes highlighted arginine (Arg) and glutamic acid (Glu) residues.*

FDA Label Image

Figure 2 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 02)

A line graph comparing the insulin secretion rate (ISR) in pmol/kg/min versus plasma glucose concentration in mg/dL for Liraglutide Injection and Placebo. Liraglutide Injection shows a higher ISR across plasma glucose levels from about 90 to 220 mg/dL compared to Placebo.*

FDA Label Image

Figure 3 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 03)

A line graph depicting mean HbA1c (%) over time (weeks) for Glimepiride and Liraglutide Injection at 1.2 mg and 1.8 mg doses. The graph shows HbA1c reduction from baseline to 52 weeks, with Liraglutide doses demonstrating greater reduction compared to Glimepiride. Statistical significance markers and a note on p values from ANCOVA analysis are included.*

FDA Label Image

Figure 4 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 04)

A line graph comparing mean HbA1c (%) over 26 weeks for Liraglutide Injection 1.2 mg, Liraglutide Injection 1.8 mg, and Sitagliptin 100 mg. The graph shows HbA1c decreasing initially and then stabilizing, with Liraglutide doses showing lower mean HbA1c than Sitagliptin throughout. Axes are labeled with Time (weeks) and Mean HbA1c (%).*

FDA Label Image

Figure 5 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 05)

A line graph comparing the percentage of patients with an event over time (months) between Placebo and Liraglutide Injection groups. The y-axis shows patients with an event (%) up to about 16%. The x-axis shows time from randomization in months up to 54. The graph includes a table of patients at risk for both groups at various time points and a hazard ratio (HR) of 0.87 with a 95% confidence interval [0.78, 0.97].*

FDA Label Image

Ifu Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 06)

Illustration of the Liraglutide Injection Pen showing labeled parts including the pen cap, rubber stopper, cartridge tip, cartridge scale, cartridge, dose display, pointer, dose selector, dose button, and flow check symbol. Additional labeled components of the needle are outer needle cap, inner needle cap, needle, and protective tab. A contact number for user support is also shown.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 2)

Illustration showing a hand holding a pen-like injector with a plunger being pulled back, indicating the preparation or priming step for an injection device. The illustration includes an arrow pointing outward from the device's tip, demonstrating the removal or ejection action associated with the device's use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 3)

An instructional illustration showing a hand holding a syringe for subcutaneous injection of LIRAGLUTIDE. The image demonstrates twisting the syringe cap upward to remove it, indicated by blue arrows.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 4)

An instructional illustration showing the preparation of a subcutaneous injection using a syringe. The image depicts a person holding the syringe near the upper arm, indicating the injection site with an arrow pointing to the skin.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 5)

An instructional illustration showing a hand holding a syringe or pen injector. The image demonstrates pulling back a needle cap or cover with an arrow indicating the direction to remove it. This is typically a step in preparing a subcutaneous injection with a liraglutide solution.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 6)

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 7)

An instructional illustration showing a close-up of hands peeling back a protective strip from a strip containing a flow check symbol for an injection device. A small inset highlights the flow check symbol with a black check mark. The illustration indicates the selection or identification of the flow check symbol for proper use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 8)

An instructional illustration showing a hand holding a prefilled injection pen with a needle cap being removed, likely demonstrating preparation for a subcutaneous injection of Liraglutide solution.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 9)

An instructional illustration showing a hand holding and pulling a blue injection device upwards. The device has a digital display with a dosage reading of "0 mg". A close-up inset highlights the needle cap removal step. This diagram likely demonstrates preparation or dose setting for a subcutaneous injection device.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 10)

An instructional illustration showing a close-up of a hand holding a pen-like injector device. The image depicts the removal of a cap or protective cover by pulling it away with an arrow indicating the direction. This likely demonstrates the first step in preparing the injection device for use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 11)

An instructional illustration showing a close-up of a hand manipulating a syringe. The image focuses on the thumb pushing a plunger or knob upward, highlighting the action needed to adjust or prepare the injection device for subcutaneous administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 12)

An instructional diagram showing a hand holding a syringe with the thumb pushing on the plunger. A blue arrow indicates the direction to push the plunger, depicting use of the injection device.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 13)

An instructional illustration showing a hand holding a syringe with a needle attached, and a finger placing or removing the needle cap, indicated by a blue arrow. The image demonstrates proper needle handling technique, likely for a subcutaneous injection.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 14)

An instructional illustration showing a close-up of a hand adjusting the dose selector on a liraglutide injection pen. The image highlights selectable doses of 0.6 mg, 1.2 mg, and 1.8 mg visible on the pen's dose window.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 15)

An illustration showing injection sites on a simplified human figure for subcutaneous administration. Highlighted areas for injection are the upper arms, stomach, and thigh, labeled accordingly.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 16)

An instructional illustration showing a hand gripping the cap of a vial of Liraglutide injection solution (6 mg/mL) for subcutaneous use. The image demonstrates the step of turning the vial cap downward, indicated by a downward blue arrow, as part of the preparation or use process.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 17)

An instructional illustration showing the injection of Liraglutide solution subcutaneously into the arm. The image depicts a hand holding a prefilled injector pen, administering the dose at a 90-degree angle with a timer indicating 6 seconds for injection duration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 18)

An instructional illustration depicting a close-up of a medical injection pen with a needle attached, showing an upward arrow indicating the direction or step for use. The image emphasizes the needle tip and the injection pen's end, likely part of usage instructions for the solution injection.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 19)

An instructional diagram depicting the connection of a needle to a pen injector for subcutaneous injection. The image shows a needle being attached to the pen with a directional arrow indicating the step to secure the needle before use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 20)

An instructional illustration showing a close-up of a hand gripping a Liraglutide injection pen, with an arrow indicating the direction to slide or pull a component, likely part of the preparation or dosing step of using the pen for subcutaneous injection.*

FDA Label Image

Label Image (Lbl500908145)

Packaging label for LIRAGLUTIDE injection, 6 mg/mL, by A-S Medication Solutions. The label indicates the product is for subcutaneous injection, with each pen containing 18 mg/3 mL (6 mg/mL). The package includes three pens and advises refrigeration without freezing. Additional details include lot number, NDC 50090-8145-0, and dosage instructions via a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.